Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

Talphera

Status and phase

Completed

Phase 3

Conditions

Moderate-to-severe Acute Pain

Treatments

Drug: sufentanil sublingual 30 mcg tablet

Study type

Interventional

Funder types

Industry

Other U.S. Federal agency

Identifiers

NCT02447848

SAP302

Details and patient eligibility

About

To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (ER) setting.

Full description

The study is a multicenter, open-label trial, in patients 18 years and older, who present to the ER with moderate-to-severe acute pain due to obvious trauma or injury evident on physical examination.

Upon meeting all entrance criteria, patients will be administered up to four doses of sufentanil 30 mcg and remain in the study for 5 hours for safety and efficacy measurements.

Safety will be monitored via periodic measurement of vital signs and continuous monitoring of oxygen saturation, as well as assessment of adverse events (AEs) and the use of concomitant medications.

Efficacy will be assessed by patient reports of pain intensity (PI) and pain relief. A Six-Item Screener (SIS) will be administered before and 1 hour after study drug administration to measure cognitive impairment. The Patient Global Assessment (PGA) and the Healthcare Professional Global Assessment (HPGA) will assess global satisfaction with the method of pain control.

Enrollment

76 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who present to the ER with moderate-to-severe pain due to obvious trauma or injury evident on physical examination.
Patients classified as American Society of Anesthesiologists (ASA) class I-III
Patients who are willing and capable of understanding and cooperating with the requirements of the study.
Patients able to understand and communicate in English.
Patients who have provided written informed consent and signed the IRB approved consent form.

Exclusion criteria

Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).
Patients who have used any illicit drugs of abuse, abused prescription medication or alcohol (4 or more drinks per day) within one year before the start of the study.
Patients with an allergy or hypersensitivity to opioids.
Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the dose of study drug.
Patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (CPAP).
Female patients who are pregnant (positive pregnancy test) or breastfeeding.
Patients with a medical condition that, in the Investigator's opinion, could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments, including chronic pain or active infection.
Patients who present to the ER using supplemental oxygen.
Patients who have participated in a clinical trial of an investigational drug or device within 30 days of enrollment.
Patients who are active or reserve duty with the US military.